FDA on breakthrough therapy requests granted by therapy area 2019

This statistic displays the share of breakthrough therapy requests granted by the FDA, by therapeutic area, in the United States, as of 2019. As of end-September of that year, 32 percent of requests for breakthrough therapies granted came from the oncology area. The FDA recommends that submissions for breakthrough therapy designations should be made prior to phase III.